arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ALNYLAM PHARMACEUTICALS, INC.

ALNY
$156.31 ▼ -4.69 (-2.92%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
75
Health
Good
Bullish
auto_awesome

Analytical Summary

ALNYLAM PHARMACEUTICALS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $20.5B
Dividend Yield —
Revenue Growth 65.2% ↗
Op. Margin 13.5% ↗
ROIC 61.7% ↗
FCF / Share $3.55 ↗
Trailing P/E 65.4x
Price / Book 26.2x
FCF Yield 2.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.71B
↑ +65.2% —
Net Income Profit after all expenses
$313.75M
↑ +212.8% —
Operating Margin Operating profit as % of sales
13.5%
↑ +271.7% 64th
FCF / Share Free cash flow per share
$3.55
↑ +1164.8% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
64
Returns
95
Financial Health
61
Cash Quality ↑
79

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 19 years · 73 quarters